Suppr超能文献

作为放射肿瘤学临床路径实施的一部分,同行评审过程:它能提高依从性吗?

A peer review process as part of the implementation of clinical pathways in radiation oncology: Does it improve compliance?

机构信息

Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.

Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.

出版信息

Pract Radiat Oncol. 2017 Sep-Oct;7(5):332-338. doi: 10.1016/j.prro.2017.01.006. Epub 2017 Jan 19.

Abstract

PURPOSE

Clinical pathways are patient management plans that standardize evidence-based practices to ensure high-quality and cost-effective medical care. Implementation of a pathway is a collaborative process in our network, requiring the active involvement of physicians. This approach promotes acceptance of pathway recommendations, although a peer review process is necessary to ensure compliance and to capture and approve off-pathway selections. We investigated the peer review process and factors associated with time to completion of peer review.

METHODS AND MATERIALS

Our cancer center implemented radiation oncology pathways for every disease site throughout a large, integrated network. Recommendations are written based upon national guidelines, published literature, and institutional experience with evidence evaluated hierarchically in order of efficacy, toxicity, and then cost. Physicians enter decisions into an online, menu-driven decision support tool that integrates with medical records. Data were collected from the support tool and included the rate of on- and off-pathway selections, peer review decisions performed by disease site directors, and time to complete peer review.

RESULTS

A total of 6965 treatment decisions were entered in 2015, and 605 (8.7%) were made off-pathway and were subject to peer review. The median time to peer review decision was 2 days (interquartile range, 0.2-6.8). Factors associated with time to peer review decision >48 hours on univariate analysis include disease site (P < .0001) with a trend toward significance (P = .066) for radiation therapy modality. There was no difference between recurrent and non-recurrent disease (P = .267). Multivariable analysis revealed disease site was associated with time to peer review (P < .001), with lymphoma and skin/sarcoma most strongly influencing decision time >48 hours.

CONCLUSIONS

Clinical pathways are an integral tool for standardizing evidence-based care throughout our large, integrated network, with 91.3% of all treatment decisions being made as per pathway. The peer review process was feasible, with <1% selections ultimately rejected, suggesting that awareness of peer review of treatment decisions encourages compliance with clinical pathway recommendations.

摘要

目的

临床路径是一种患者管理计划,用于标准化基于证据的实践,以确保高质量和具有成本效益的医疗护理。在我们的网络中,实施路径是一个协作过程,需要医生的积极参与。这种方法促进了对路径建议的接受,尽管需要进行同行评审过程以确保合规性,并捕获和批准偏离路径的选择。我们调查了同行评审过程以及与完成同行评审时间相关的因素。

方法和材料

我们的癌症中心在一个大型综合网络中为每个疾病部位实施了放射肿瘤学路径。建议是根据国家指南、已发表的文献以及机构对疗效、毒性和成本进行分层评估的经验编写的。医生将决策输入到一个在线、菜单驱动的决策支持工具中,该工具与病历集成。从支持工具中收集数据,包括在线和离线选择的比例、疾病部位主任进行的同行评审决策以及完成同行评审的时间。

结果

2015 年共输入了 6965 项治疗决策,其中 605 项(8.7%)偏离路径,需要进行同行评审。同行评审决策的中位数时间为 2 天(四分位距,0.2-6.8)。单变量分析中,与同行评审决策时间>48 小时相关的因素包括疾病部位(P<.0001),放射治疗方式也有显著趋势(P=.066)。复发性和非复发性疾病之间没有差异(P=.267)。多变量分析显示疾病部位与同行评审时间相关(P<.001),淋巴瘤和皮肤/肉瘤对>48 小时的决策时间影响最大。

结论

临床路径是我们大型综合网络中标准化基于证据的护理的重要工具,91.3%的治疗决策都是按照路径进行的。同行评审过程是可行的,只有<1%的选择最终被拒绝,这表明对治疗决策同行评审的认识鼓励了对临床路径建议的遵守。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验